

Expert Second Opinion: Current and Future Roles of Immunotherapy and Targeted Therapy in the Management of Advanced Gastroesophageal Cancers — Microlearning Activity 3

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What is the PD-L1 combined positive score (CPS) threshold recommended by the FDA to indicate the use of immune checkpoint inhibition for patients with squamous cell carcinoma or adenocarcinoma of the gastroesophageal junction?
 - a. CPS ≥ 1
 - b. CPS ≥ 5
 - c. CPS ≥ 10
 - d. PD-L1 expression is not used to guide immunotherapy in this setting
2. Squamous cell carcinomas are generally more susceptible to immune checkpoint inhibitors than adenocarcinomas.
 - a. True
 - b. False
3. Which of the following statements best describes the relationship between biomarker assessment and the site of biopsy in advanced gastroesophageal cancers?
 - a. Biomarker expression is consistent across all tumor sites, regardless of where the biopsy is obtained
 - b. Biomarker testing is clinically relevant only when performed on metastatic lesions
 - c. The biomarker profile may vary according to the site of biopsy because of tumor heterogeneity
4. Which of the following descriptions best represents the sensitivity and specificity of circulating tumor DNA assays in detecting HER2 amplification?
 - a. High sensitivity and high specificity
 - b. Limited sensitivity but high specificity
 - c. High sensitivity but limited specificity
 - d. Limited sensitivity and limited specificity